Sieber Martin A, Lengsfeld Philipp, Walter Jakob, Schirmer Heiko, Frenzel Thomas, Siegmund Fred, Weinmann Hanns-Joachim, Pietsch Hubertus
Research Diagnostic Imaging Bayer Schering Pharma AG, Berlin, Germany.
J Magn Reson Imaging. 2008 May;27(5):955-62. doi: 10.1002/jmri.21368.
To investigate the role of excess ligand present in gadolinium (Gd) -based contrast agents in the development of nephrogenic systemic fibrosis (NSF). Using a dosing regimen to simulate the exposure seen in patients with severe renal impairment, we investigated the effect of excess ligand on Gd-deposition and the depletion of endogenous ions.
Gadodiamide and gadoversetamide were formulated with 0%, 5%, and 10% excess ligand. Forty-two, healthy, male Hannover Wistar rats received daily intravenous injections of each formulation over a period of 20 days. At the end of the study, histopathological analysis of the skin was performed and the concentrations of Gd, Zn, and Cu were measured in several tissues. The levels of Zn in the urine were also measured.
The most severe skin lesions were observed after injection of formulations containing 0% free ligand and in those animals with the highest Gd concentrations in the skin. There were no significant reductions in the levels of Zn or Cu observed in the skin; however, the levels of Zn in the urine were elevated following administration of formulations with the highest amount of excess ligand.
Our findings suggest that there is an inverse correlation between the amount of excess ligand present in Gd-containing contrast agents and the amount of Gd in the tissue, and further underline the importance of the inherent stability of these agents in the development of NSF.
研究钆(Gd)基造影剂中存在的过量配体在肾源性系统性纤维化(NSF)发展中的作用。我们采用一种给药方案来模拟严重肾功能损害患者的暴露情况,研究过量配体对钆沉积和内源性离子消耗的影响。
将钆双胺和钆塞酸二钠分别与0%、5%和10%的过量配体进行配制。42只健康雄性汉诺威Wistar大鼠在20天内每天接受每种制剂的静脉注射。在研究结束时,对皮肤进行组织病理学分析,并测量多个组织中钆、锌和铜的浓度。同时也测量了尿液中的锌水平。
在注射不含游离配体的制剂后以及皮肤中钆浓度最高的动物中观察到最严重的皮肤病变。皮肤中锌或铜的水平没有明显降低;然而,给予过量配体含量最高的制剂后,尿液中的锌水平升高。
我们的研究结果表明,含钆造影剂中过量配体的量与组织中钆的量呈负相关,并进一步强调了这些制剂的固有稳定性在NSF发展中的重要性。